Robert G. Gish MD, FAASLD
Principal, Robert G. Gish Consultants LLC; Clinical Professor of Medicine & Staff Physician, Loma Linda University Liver Transplant Institute, Las Vegas, Nevada; Adjunct Professor of Medicine, University of Nevada, Reno, Nevada; Adjunct Professor of Medicine, University of Nevada, Las Vegas, Nevada; Adjunct Professor of Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, California; Medical Director, Hepatitis B Foundation, Doylestown, PennsylvaniaDr. Gish was first in Pharmacy School at the University of Kansas and then obtained his medical degree from the University of Kansas Medical School in Kansas City, Kansas. He completed a 3-year internal medicine residency at the University of California, San Diego, and a 4-year gastroenterology and hepatology fellowship at the University of California, Los Angeles which included transplant medicine.
Dr. Gish is a fellow of the American Association for the Study of Liver Disease, the American Society of
Transplantation and American College of Physicians.
He has served on the editorial boards of American Journal of Gastroenterology, Hepatology, Journal of Hepatology, Digestive Diseases and Sciences, and Gastroenterology, among many others. He co-authored a public health policy for liver health in Vietnam focusing on HBV and is also assisting with the development of viral hepatitis health care policies in Georgia, Armenia, and the Philippines. He was a major early contributor to decipherment methods for the detection of hepatitis B and C virus and characterizing its epidemiology and clinical presentation in humans. He was involved in studies that led to the genotypic classification strategies and methods now in use worldwide. He has published more than 700 original articles, abstracts, and book chapters.
Robert G. Gish, MD, is currently an Adjunct Professor of Medicine at the University of Nevada Schools of Medicine in Las Vegas and in Reno. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University as well as a Staff Physician at Loma Linda University’s Liver Transplant Clinic in Las Vegas. In addition, he is also Medical Director of the Asia Pacific Health Foundation in San Diego, CA and of the Hepatitis B Foundation in Doylestown, Pennsylvania. Dr. Gish is currently seeing patients, both in-person and via telemedicine, at various clinics in San Diego, Folsom, Fresno, San Jose and Las Vegas/Reno.
Disclosures
Dr. Gish reports the following:
Over 80% of income from Pharma derived from Dr. Gish’s work and consultation activities is directed to research, education, public policy and/or donated to charitable organizations.
Pharmaceutical Company Relationships
Dr. Robert Gish: Financial Disclosures relative to the pharmaceutical industry that are as follows:
Robert Gish, MD, has had a financial interest/relationship or affiliation in the form of:
Grants/Research Support in last 2 years:
Gilead
Dr. Gish has performed as Consultant and/or Advisor to (in the last two years):
Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, Viking Therapeutics
Current Activity with Scientific or Clinical Advisory Boards:
Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, HepQuant, Intercept, Janssen
Current Clinical Trials Alliance:
Topography Health
Chair Clinical Advisory Board:
Prodigy
Advisory Consultant: Diagnostic Companies:
Biocollections, Fujifilm/Wako, Quest
Data Safety Monitoring Board:
Arrowhead
Consulting Confidentiality Agreements as of 2020:
Abbvie: 2017-current
Abbott: 2016-current
Access Biologicals: 2016-current
ADMA Biologics: 2017-current
AEC Partners: 2017-current
Aligos Therapeutics: 2020-current
Arena Pharmaceuticals Inc: 2018-current
Arrowhead: 2011-current
Arterys Inc: 2018 - current
Alexion: 2018-current
Altimmune: 2020-current
Antios Therapeutics: 2018-current
AprosTx: 2020-current
Bayer: 2019-current
Cirina: 2017-current
Consumer Health Products Assoc: 2019-current
DiaSorin Inc: 2020-current
Dova Pharmaceuticals: 2017-current
DRG Abacus: 2018-current
DURECT Corporation: 2020-current
Dynavax: 2018-current
Echosens: 2020-current
Eiger: 2015-current
Enyo: 2017-current
Exelixis: 2018-current
Forty-Seven Inc: 2019-current
Fujifilm Wako Diagnostics: 2019-current
Gilead: 2018-current
HepQuant: 2018-current
HepaTx: 2017-current
IDLogiq: 2020-current
Intellia: 2015-current
Intercept 2010 to current: approved to discuss what is in the public domain
Inotek: 2017-current
Iqvia: 2018-current
Janssen/J&J: 2015-current
KannaLife: 2019-current
Laboratory for Advanced Medicine: 2019-current
Labyrinth Holdings: 2017-current
Lilly: 2017-current
MedImmune: 2015-current
Merck: 2017-current
New Enterprise Associates: 2020-current
Ogilvy CommonHealth: 2017-current
Organovo: 2017-current
Patient Connect: 2017-current
ProdigY Biotech: 2020-current
Prometheus Laboratories: 2017-current
Refuah Solutions: 2020-current
Regulus Therapeutics: 2019-current
Salix: 2019-current
Shionogi Inc: 2017-current
Spring Bank: 2018-current
Trimaran: 2017-current
Speakers Bureau:
These speaker bureau activities focus on HBV, HCV, and liver cancer; specifically, epidemiology, diagnosis, and treatment. In addition, program presentations on vaccination for HBV and management of complications of cirrhosis.
Dr. Gish has a speaker’s contract to do promotional talks for: AbbVie, Bayer, BMS, Eisai, Gilead Sciences Inc., Intercept, Salix
Minor stock shareholder (liver space noted only):
RiboSciences, CoCrystal
Stock Options: Eiger, Genlantis, HepQuant, AngioCrine
Other Financial Support or Material Support: None
Full details of all current and historical Research Grant Support– See my current CV Leadership Position, Other than Employment other than at Stanford University– None
Expert Testimony for Pharma (Intellectual Property) in the last 7 years– Janssen (expert witness in a litigation case), USP Pharma (expert witness in a litigation case)
Leadership Position, Other than Employment: None
Other Remuneration from Pharma: None
Recent Contributions to PracticeUpdate:
- Bulevirtide Monotherapy in Patients With HDV-Related Compensated Cirrhosis and Clinically Significant Portal Hypertension
- Factors Affecting Outcome and Treatment Response in Patients With Chronic Hepatitis Delta
- Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B
- Risk of HBsAg Seroreversion After Corticosteroid Treatment in Patients With Previous Hepatitis B Virus Exposure
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
- Pre-Procedure Avatrombopag Reduces Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia
- Higher Risk of Renal Disease in Chronic Hepatitis C Patients: Antiviral Therapy Survival Benefit in Patients on Hemodialysis
- Oral Prenylation Inhibition With Lonafarnib in Chronic Hepatitis D Infection